An economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol

被引：0
|
作者：
Russell, JM [1 ]
Mackell, JA [1 ]
机构：
[1] Univ Texas, Med Branch, Galveston, TX 77550 USA
来源：
SCHIZOPHRENIA RESEARCH | 2003年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0920-9964(03)80345-6
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [1] An economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol
    Russell, JM
    Mackell, JA
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S315 - S316
  • [2] Economic consequences of the adverse reactions related with antipsychotics:: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain
    Bobes, J
    Cañas, F
    Rejas, J
    Mackell, J
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (08): : 1287 - 1297
  • [3] Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study
    Alptekin, Koksal
    Hafez, Jamal
    Brook, Shlomo
    Akkaya, Cengiz
    Tzebelikos, Errikos
    Ucok, Alp
    El Tallawy, Hamdy
    Danaci, Aysen-Esen
    Lowe, Wing
    Karayal, Onur N.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2009, 24 (05) : 229 - 238
  • [4] THE RELEVANCE OF DOSES FOR COMPARING HALOPERIDOL, RISPERIDONE AND OLANZAPINE
    Fischer-Barnicol, D.
    Koch, H.
    Lanquillon, S.
    Haen, E.
    Leucht, S.
    Stoppe, G.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [5] Antipsychotic treatments for schizophrenia: A cost-effectiveness analysis comparing haloperidol, olanzapine, risperidone and ziprasidone.
    Augustovski, F
    Krupitzky, H
    Laffaire, E
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 162 - 162
  • [6] Efficacy and tolerability of switching from olanzapine, risperidone and haloperidol to ziprasidone in patients with schizophrenia: An international multi-center study
    Alptekin, K.
    Karayal, O. N.
    Brook, S.
    Akkaya, C.
    Tzebelikos, E.
    EUROPEAN PSYCHIATRY, 2008, 23 : S122 - S123
  • [7] Cost Analysis of the Treatment of Schizophrenia in the UKA Simulation Model Comparing Olanzapine, Risperidone and Haloperidol
    Stephen Almond
    Owen O’Donnell
    PharmacoEconomics, 2000, 17 : 383 - 389
  • [8] Cost analysis of the treatment of schizophrenia in the UK - A simulation model comparing olanzapine, risperidone and haloperidol
    Almond, S
    O'Donnell, O
    PHARMACOECONOMICS, 2000, 17 (04) : 383 - 389
  • [9] Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models
    Brinholi, Francis Fregonesi
    de Farias, Carine Coneglian
    Bonifacio, Kamila Landucci
    Higachi, Luciana
    Casagrande, Rubia
    Moreira, Estefania Gastaldello
    Barbosa, Decio Sabbatini
    BIOMEDICINE & PHARMACOTHERAPY, 2016, 81 : 411 - 415
  • [10] What antipsychotic is more effective? Pafip three years longitudinal study comparing haloperidol, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole
    Gomez Revuelta, M.
    Alonso Alvarez, P.
    Garcia Egea, J. L.
    Juncal Ruiz, M.
    Porta Olivares, O.
    Sanchez Blanco, L.
    Abejas Diez, D.
    de Santayana Jenaro, G. Pardo
    Landera Rodriguez, R.
    EUROPEAN PSYCHIATRY, 2017, 41 : S81 - S81
12345